###begin article-title 0
###xml 92 96 92 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3</italic>
###xml 18 23 <span type="species:ncbi:9606">human</span>
Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3</italic>
###xml 168 173 168 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 327 332 327 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 92 97 <span type="species:ncbi:9606">human</span>
###xml 289 294 <span type="species:ncbi:9606">human</span>
Expression of the putative Wnt signalling inhibitor Dickkopf-3 (DKK3) is frequently lost in human cancer tissues because of aberrant 5'-cytosine methylation within the DKK3 gene promoter. Since other Wnt signalling inhibitors have been reported to be targets of epigenetic inactivation in human breast cancer, we questioned if DKK3 expression is also epigenetically silenced during breast carcinogenesis and therefore might contribute to oncogenic Wnt signalling commonly found in this disease.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 236 245 236 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 544 551 <span type="species:ncbi:9606">patient</span>
DKK3 mRNA expression and DKK3 promoter methylation were determined by RT-PCR, realtime PCR and methylation-specific PCR in breast cell lines (n = 9), normal breast tissues (n = 19) and primary breast carcinomas (n = 150), respectively. In vitro DNA demethylation was performed by incubating breast cell lines with 5-aza-2'-deoxycytidine and trichostatin A. DKK3 protein expression was analysed by immunohistochemistry in breast carcinomas (n = 16) and normal breast tissues (n = 8). Methylation data were statistically correlated with clinical patient characteristics. All statistical evaluations were performed with SPSS 14.0 software.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 286 291 286 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 337 342 337 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 396 401 396 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 499 504 499 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 617 622 617 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 731 736 731 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 832 839 <span type="species:ncbi:9606">patient</span>
DKK3 mRNA was downregulated in 71% (five of seven) of breast cancer cell lines and in 68% of primary breast carcinomas (27 of 40) compared with benign cell lines and normal breast tissues, respectively. A DNA demethylating treatment of breast cell lines resulted in strong induction of DKK3 mRNA expression. In tumourous breast tissues, DKK3 mRNA downregulation was significantly associated with DKK3 promoter methylation (p < 0.001). Of the breast carcinomas, 61% (92 of 150) revealed a methylated DKK3 promoter, whereas 39% (58 of 150) retained an unmethylated promoter. Loss of DKK3 expression in association with DKK3 promoter methylation (p = 0.001) was also confirmed at the protein level (p < 0.001). In bivariate analysis, DKK3 promoter methylation was not associated with investigated clinicopathological parameters except patient age (p = 0.007).
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 168 173 168 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 254 259 254 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 101 106 <span type="species:ncbi:9606">human</span>
DKK3 mRNA expression and consequently DKK3 protein expression become frequently downregulated during human breast cancer development due to aberrant methylation of the DKK3 promoter. Since DKK3 is thought to negatively regulate oncogenic Wnt signalling, DKK3 may be a potential tumour suppressor gene in normal breast tissue.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 30 33 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK</italic>
###xml 183 184 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 240 244 240 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK1</italic>
###xml 246 251 246 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK2 </italic>
###xml 255 260 255 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK4 </italic>
###xml 376 377 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 393 398 390 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 438 439 435 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 440 441 437 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 442 443 439 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 596 597 590 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 634 635 628 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 636 637 630 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 662 667 656 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 940 942 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1008 1010 1002 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1152 1153 1143 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 574 579 <span type="species:ncbi:9606">human</span>
The mammalian Dickkopf genes (DKK) encode a class of extracellular signalling molecules that control cell fate during embryonic development and regulate tissue homeostasis in adults [1,2]. Four DKK gene members have been identified so far. DKK1, DKK2 and DKK4 antagonise canonical Wnt/beta-catenin signalling by interaction with LDL-receptor-related proteins (LRP5 and LRP6) [3]. In contrast, DKK3 does not sequester LRPs or Wnt ligands [2,4,5]. Its function in antagonising nuclear beta-catenin levels, designated as the hallmark of an activated Wnt pathway often found in human tumour tissues [6], has received conflicting reports [7-9]. Most evidence suggest DKK3 exerts a tumour suppressive function by inhibiting a non-canonical Wnt signalling branch referred to as the planar cell polarity (PCP) pathway. The PCP pathway is characterised by the activation of c-Jun kinase (JNK) via recruitment of small GTPases of the Rho/Rac family [10]. It results in changes in cell adhesion, motility and polarity [11] rather than interfering with the networks of proliferation and differentiation, which is mediated by canonical Wnt/beta-catenin signalling [6].
###end p 11
###begin p 12
###xml 60 61 60 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 62 64 62 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 65 67 65 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 235 236 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 405 410 405 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 569 571 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 623 628 623 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 773 775 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 809 814 809 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 878 883 878 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1011 1013 1011 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1036 1038 1036 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1175 1180 1175 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1286 1288 1286 1288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1310 1315 1310 1315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1461 1466 1461 1466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1548 1550 1548 1550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1658 1660 1658 1660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1666 1671 1666 1671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1794 1799 1794 1799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1936 1938 1936 1938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1989 1991 1989 1991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 102 107 <span type="species:ncbi:9606">human</span>
###xml 857 862 <span type="species:ncbi:10090">mouse</span>
In agreement with its putative tumour-suppressive function [9,12-14]DKK3 is commonly downregulated in human cancers such as lung cancer [15-17], renal clear cell carcinoma [18], pancreatic cancer [19], leukaemia [20], prostate cancer [7,21], bladder cancer [22], melanoma [23] and gastrointestinal tumours [24]. In many of these diseases transcriptional loss is tightly associated with methylation of the DKK3 promoter [15,16,18,20-22,24], whereas in other malignancies the cause of downregulation remains to be elucidated or is not related to 5'-cytosine methylation [23]. A study on lung cancer revealed that the rate of DKK3 methylation increased steadily from normal lung tissue, to low-grade and high-grade atypical adenomatous hyperplasia to invasive adenocarcinoma [25], suggesting a potential role of DKK3 methylation in lung cancer progression. In mouse cancer models, DKK3 has proved a promising therapeutic agent capable of repressing tumour progression, for example, in testicular germ cell cancer [14] and prostate cancer [13]. More recently, a breast cancer xenotransplantation model demonstrated that a single adenoviral-mediated intra-tumoural injection of a DKK3 expression vector efficiently discontinued tumour growth, with the induction of apoptosis in these cells [26]. This suggests that DKK3 may have an important tumour-suppressive function that either prevents tumour initiation or attenuates cancer progression. Interestingly, loss of DKK3 expression was first observed in numerous immortalised tumour-derived cell lines [27]. Immortalisation, that is escape from cellular senescence, is an early event in malignant transformation [28], so DKK3 could act as a tumour suppressor gene by mediating the effects of senescence stimuli. In concordance with this hypothesis, DKK3 expression was found to be elevated in organs with predominantly growth-arrested post-mitotic cells, for example in the heart and brain [29] and also in senescent prostate epithelial cells [30].
###end p 12
###begin p 13
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 176 181 176 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 226 231 226 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 380 385 380 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 503 508 503 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 427 432 <span type="species:ncbi:9606">human</span>
However, to the authors' knowledge, a comprehensive study on DKK3 gene regulation and its implication in breast cancer has not yet been published. In our study we investigated DKK3 mRNA expression, DKK3 protein expression and DKK3 promoter methylation in breast cell lines as well as in normal and malignant primary breast tissues. Our results demonstrate for the first time that DKK3 expression is frequently downregulated in human breast cancer as a consequence of aberrant DNA methylation within the DKK3 gene promoter.
###end p 13
###begin title 14
Materials and methods
###end title 14
###begin title 15
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient material
###end title 15
###begin p 16
###xml 736 744 736 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 817 818 817 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
###xml 470 478 <span type="species:ncbi:9606">patients</span>
###xml 774 781 <span type="species:ncbi:9606">Patient</span>
Nineteen matched tumour and normal tissue samples from breast cancer patients and 131 tissue samples from breast carcinomas were obtained from patients treated by primary surgery for breast cancer at the Departments of Gynecology at the University Hospitals of Aachen, Jena, Regensburg and Dusseldorf, Germany, between 1991 and 2005. The selection of cases was based on availability of tissue, and the sample was recruited in a non-selective, consecutive manner. Female patients presenting with unilateral, invasive breast cancer with no individual breast cancer history were included in the study. Exclusion criteria were: neo-adjuvant chemotherapy before surgery; presentation with secondary breast cancer; or peritumourous carcinoma in situ present in the tumour sample. Patient characteristics are shown in Table 1.
###end p 16
###begin p 17
###xml 25 32 <span type="species:ncbi:9606">patient</span>
Demographic and clinical patient characteristics of primary breast carcinomas (n = 150)
###end p 17
###begin p 18
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 76 77 76 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 171 172 171 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
1Only female patients with unilateral invasive breast cancer were included. 2According to International Union Against Cancer: TNM Classification of Malignant Tumours [32].3IRS = immunoreactivity score [35]. n.a. = not available.
###end p 18
###begin p 19
###xml 4 12 <span type="species:ncbi:9606">patients</span>
All patients gave informed consent for retention and analysis of their tissue for research purposes and the Institutional Review Boards of the participating centres approved the study.
###end p 19
###begin p 20
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
Tumour histology was determined according to the criteria of the World Health Organization [31], while disease stage was assessed according to International Union Against Cancer [32]. Tumours were graded according to Bloom and Richardson, as modified by Elston and Ellis [33]. After surgery, tumour material was immediately snap-frozen in liquid nitrogen. Sections stained with haematoxylin and eosin were prepared for assessing the percentage of tumour cells; only samples containing more than 70% tumour cells were selected. Samples were dissolved in lysis buffer followed by DNA isolation using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations.
###end p 20
###begin title 21
Breast cell lines
###end title 21
###begin p 22
The cancerous breast cell lines BT20, Hs578T, MCF7, MDA-MB231, SKBR3, T47D and ZR75-1 and the non-cancerous lines HMEC and MCF12A were obtained from the American Type Culture Collection (ATCC) (Rockville, MA, USA) and cultured under recommended conditions.
###end p 22
###begin title 23
RNA expression analysis
###end title 23
###begin p 24
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 250 251 250 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
RNA isolation, RT-PCR and realtime PCR were performed as previously described [34]. To ensure experiment accuracy, all quantitative measurements were performed in triplicate. Intron-spanning primer sequences and cycling conditions are given in Table 2.
###end p 24
###begin p 25
Oligonucleotide primers used in the study
###end p 25
###begin p 26
###xml 1 3 1 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
TA = annealing temperature.
###end p 26
###begin title 27
Bisulphite-modification and methylation-specific PCR
###end title 27
###begin p 28
###xml 236 238 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 292 293 291 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 339 344 338 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
About 1 mug of genomic DNA was bisulphite-modified using the EZ DNA Methylation Kit (Zymo Research, Orange, CA, USA) according to the manufacturer's recommendations. Methylation-specific PCR (MSP) was performed as previously described [34]. Primers and cycling conditions are listed in Table 2. Specificity of MSP primers in detecting the DKK3 methylation status were demonstrated using universal unmethylated and universal polymethylated DNA as a template (Epi Tect Control DNA Set; Qiagen, Hilden, Germany).
###end p 28
###begin title 29
5-aza-2'-deoxycytidine and trichostatin A treatment
###end title 29
###begin p 30
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
DNA demethylating treatment of breast cancer cell lines was performed with 5-aza-2'-deoxycytidine as described elsewhere [34], modified by the addition of 300 nM of the histone deacetylase inhibitor trichostatin A (Sigma-Aldrich, Deisenheim, Germany) on day three (incubation for 24 hours). Drug concentrations were adjusted in advance to warrant viability and replication of all cell lines.
###end p 30
###begin title 31
Immunohistochemistry
###end title 31
###begin p 32
###xml 749 751 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 835 836 834 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
Formalin-fixed, paraffin-embedded 2 mum tissue sections were subjected to immunostaining using the Advance Kit (Dako, Hamburg, Germany) following the manufacturer's instructions. Antigen retrieval was performed by pre-treatment with citrate buffer (pH 7) in a microwave oven (20 minutes at 200 W). Sections were incubated for 30 minutes with the primary antibody (AP1523a, Abgent, San Diego, CA, USA; 1:50), washed and incubated for 10 minutes with the secondary antibody (biotinylated polylink; Dako, Hamburg, Germany). Diaminobenzidin (Dako, Hamburg, Germany) was used for antibody detection. An experienced breast cancer pathologist (N.B.) scored the immunohistochemical staining according to the scoring system suggested by Remmele and Stegner [35]. The tissue specimens for immunohistochemical analysis are characterised in Table 3.
###end p 32
###begin p 33
Immunohistochemical analysis of DKK3 protein expression in breast cancer samples (n = 16) in relation to clinicopathological parameters
###end p 33
###begin p 34
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 96 97 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 136 137 136 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 201 202 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
1According to International Union Against Cancer: TNM Classification of Malignant Tumours [32]. 2According to Remmele and Stegner [35]. 3According to Remmele and Stegner [35] as a continuous variable. 4Matched normal breast epithelial tissue. IRS = immunoreactivity score. IDC = invasive ductal carcinoma. ILC = invasive lobular carcinoma. n.a. = not available.
###end p 34
###begin title 35
Statistical evaluations
###end title 35
###begin p 36
###xml 260 265 260 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 290 295 290 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 475 480 475 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
Statistical analyses were completed using SPSS 14.0 (SPSS, Chicago, IL, USA). Differences were considered significant when p < 0.05. A non-parametric Mann-Whitney U-test and a Kruskal-Wallis test were applied to examine expression levels among normal tissues, DKK3 unmethylated tumours and DKK3 methylated tumours. A student's t-test was applied on the expression of paired normal and tumour samples. To study statistical associations between clinicopathological factors and DKK3 methylation status contingency tables and a two-sided Fisher's exact test were used.
###end p 36
###begin title 37
Results
###end title 37
###begin title 38
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
Differential DKK3 mRNA expression in breast cell lines
###end title 38
###begin p 39
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 362 367 362 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 446 451 446 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 582 587 582 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 301 306 <span type="species:ncbi:9606">human</span>
To start our analysis of DKK3 expression in breast cancer patients we analysed mRNA expression in non-malignant and malignant breast cell lines using realtime PCR. Strong DKK3 expression could be detected in non-malignant HMEC and MCF12A cells (Figure 1a) exhibiting expression levels comparable with human placental tissue, which is known to abundantly express DKK3 [22]. Among the malignant cell lines, Hs578T and SKBR3 cells revealed abundant DKK3 mRNA levels comparable with benign breast cells. In five further breast cancer cell lines (BT20, MCF7, MDA-MB231, T47D and ZR75-1) DKK3 expression was substantially reduced.
###end p 39
###begin p 40
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 0 80 0 80 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>DKK3 </italic>mRNA expression and <italic>DKK3 </italic>promoter methylation analysis in breast cell lines</bold>
###xml 82 86 82 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 333 338 333 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 432 437 432 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 497 502 497 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 514 518 514 518 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 542 547 542 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 801 806 801 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1020 1025 1020 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1174 1179 1174 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1334 1339 1334 1339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 357 362 <span type="species:ncbi:9606">human</span>
DKK3 mRNA expression and DKK3 promoter methylation analysis in breast cell lines. (a) DKK3 mRNA expression is differentially expressed in breast cell lines. Non-cancerous cell lines (HMEC and MCF12A) and cancerous breast cell lines (Hs578T, SKBR3, BT20, MCF7, MDA-MB231, T47D and ZR75-1) were analysed by realtime PCR and related to DKK3 mRNA expression in human placental tissue (set to 1). Grey bars = samples expressing abundant DKK3 mRNA; black bars = samples showing strong downregulation of DKK3 expression. (b) Hypermethylation of the DKK3 promoter in breast cell lines. Methylation specific PCR (MSP) was performed with bisulphite-treated DNA from benign and malignant breast cell lines. DNA bands in lanes labelled with U indicate PCR products amplified with primers recognising unmethylated DKK3 promoter sequence. DNA bands in lanes labelled with M represent amplificate generated with methylation-specific primers; water served as 'no template control' (NTC). MSP controls demonstrate the specificity of the DKK3 primers used. Universal poly-methylated bisulphite-converted DNA (UMD) exclusively yields amplification products with primers specific to methylated DKK3 promoter sequence; universal unmethylated bisulphite-converted DNA (UUD) yields exclusive amplification products with primers recognising the unmethylated DKK3 promoter sequence.
###end p 40
###begin title 41
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
Methylation of the DKK3 promoter in breast cell lines
###end title 41
###begin p 42
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 203 208 203 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 372 377 372 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 429 434 429 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 493 495 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 523 528 523 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 624 629 624 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 594 599 <span type="species:ncbi:9606">human</span>
Aberrant promoter hypermethylation of tumour suppressor genes during carcinogenesis is an effective mechanism resulting in downregulation and functional inactivation of these genes [36,37]. Knowing that DKK3 expression was downregulated in most malignant breast cell lines we performed promoter methylation analysis in these cells. By using MSP [38] we found a methylated DKK3 promoter sequence in all cell lines showing reduced DKK3 expression, BT20, MCF7, MDA-MB231, T47D and ZR75-1 (Figure 1b). In contrast to this, all DKK3 expressing cell lines (HMEC, MCF12A, Hs578T and SKBR3) as well as human placental tissue lacked DKK3 promoter methylation in the analysed promoter region.
###end p 42
###begin title 43
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
In vitro demethylation of the DKK3 promoter
###end title 43
###begin p 44
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 72 77 72 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 287 292 287 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 317 322 317 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 635 640 635 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 665 670 665 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 750 752 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 766 771 766 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 837 842 837 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 885 890 885 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
To prove a direct association of DKK3 promoter methylation with loss of DKK3 mRNA expression we treated seven breast cell lines sequentially with the DNA-methyltransferase inhibitor 5-aza-2'-deoxycytidine and the histone deacetylase inhibitor trichostatin A. Subsequently, we determined DKK3 promoter methylation and DKK3 mRNA expression before and after the drug treatment. MSP analyses after the treatment (Figure 2a) confirmed that promoter demethylation had occurred in all methylated cell lines by the appearance and enhancement of signals indicative of unmethylated DNA sequences. Those cell lines initially bearing a methylated DKK3 promoter showed elevated DKK3 mRNA expression after treatment (BT20, MCF7, MDA-MB231, T47D and ZR75-1; Figure 2b), whereas no DKK3 mRNA gain was achieved in unmethylated MCF12A and only a marginal DKK3 mRNA gain in SKBR3 cells. The induction of DKK3 mRNA transcription after the treatment as determined by realtime PCR ranged from 4.7-fold to 29-fold higher than in originally methylated breast cancer cells.
###end p 44
###begin p 45
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 27 36 27 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 0 53 0 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>DKK3 </italic>mRNA expression after <italic>in vitro </italic>DNA demethylation</bold>
###xml 55 59 55 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 59 68 59 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 299 303 298 302 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 320 325 319 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 421 426 420 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 454 459 453 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 535 540 534 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
DKK3 mRNA expression after in vitro DNA demethylation. (a) In vitro demethylation of the DKK3 promoter. Methylation specific PCR of seven breast cell lines was performed with DNA from cells either untreated (-) or treated with 1 muM 5-aza-2'-deoxycytidine (DAC) and 300 nM trichostatin A (TSA) (+). (b) Re-expression of DKK3 mRNA in breast cell lines after treatment with DAC/TSA. All cell lines initially exhibiting low DKK3 mRNA restored expression of DKK3 compared with the untreated control cells. Induction level (fold change) of DKK3 mRNA expression was determined by realtime PCR.
###end p 45
###begin title 46
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
Differential DKK3 mRNA expression in primary breast carcinomas
###end title 46
###begin p 47
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 224 229 224 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
DKK3 mRNA expression in primary breast tissues was then examined by realtime PCR. In the first step, 19 pairs of breast carcinoma tissues and corresponding normal breast tissue were analysed. A significant downregulation of DKK3 mRNA expression in tumour tissue compared with its adjacent normal tissue was detected in 14 (74%) of the 19 pairs (Figure 3a), as defined by an expression fold change of two or more (FC2).
###end p 47
###begin p 48
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 0 58 0 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>DKK3 </italic>mRNA expression analysis in primary breast carcinomas</bold>
###xml 60 64 60 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 80 85 80 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 129 131 129 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 244 248 244 248 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 257 262 257 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 517 522 517 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
DKK3 mRNA expression analysis in primary breast carcinomas. (a) Realtime PCR of DKK3 mRNA expression in 19 matched pairs (normal vs. tumour). Arrowheads indicate downregulation in the tumour by an expression fold change of more than two (FC2). (b) Relative DKK3 mRNA expression in 40 additional breast cancer specimens. Mean expression of 19 normal breast tissues (N) was set to 1. Based on a FC2, grey bars represent tumour specimens (T) showing normal expression, black bars represent tumour specimens with reduced DKK3 mRNA expression.
###end p 48
###begin p 49
###xml 149 154 149 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 188 193 188 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 286 291 286 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 464 469 464 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 528 536 <span type="species:ncbi:9606">patients</span>
To further support this data set we analysed 40 additional breast carcinomas with no corresponding normal breast tissue and referred each individual DKK3 mRNA expression level to the mean DKK3 expression of the previously analysed 19 normal breast tissues (Figure 3b). The frequency of DKK3 mRNA downregulation measured in this tumour cohort (27 of 40, 68% by FC2) is in good agreement to the result achieved with the 19 matched pairs. Therefore downregulation of DKK3 mRNA in breast cancer is considered to affect about 70% of patients.
###end p 49
###begin title 50
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
DKK3 promoter methylation in primary breast carcinomas
###end title 50
###begin p 51
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 255 260 255 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 308 309 308 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 352 357 352 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 497 498 497 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 678 683 678 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 929 934 929 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 991 993 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 852 857 <span type="species:ncbi:9606">human</span>
To address the question of whether DKK3 promoter methylation occurs in primary breast carcinomas, we analysed 150 mammary tumour samples by MSP. Corresponding normal breast tissue was available for 19 tumours. In total, 92 of 150 tumours (61.3%) revealed DKK3 promoter methylation (for example, #7 in Figure 4) whereas in 58 of 150 tumours (38.7%) the DKK3 promoter was unmethylated. In these cases, MSP amplification signals were obtained exclusively in the U-reaction (for example, #5 in Figure 4). Of the normal breast tissues, only a single sample (5.3% of 19 samples) gave a very weak methylation signal (data not shown) in contrast to all other normal tissues that lacked DKK3 promoter methylation. As an additional control that infiltrating immune cells do not contribute to methylation signals in mammary tumours, bisulphite-converted DNA from human peripheral blood lymphocytes were assayed and revealed an unmethylated DKK3 promoter, consistent with results from a previous study [39].
###end p 51
###begin p 52
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 0 63 0 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>DKK3 </italic>promoter methylation analysis in primary breast carcinomas</bold>
###xml 323 328 323 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 227 232 <span type="species:ncbi:9606">human</span>
DKK3 promoter methylation analysis in primary breast carcinomas. Methylation specific PCR results from 10 representative matched pairs of primary breast tumour (T) and corresponding normal breast tissue (N) are shown. DNA from human placenta (Plc) as well as from peripheral blood lymphocytes (Lyc) reveals an unmethylated DKK3 promoter. DNA from breast carcinoma cell line BT20 served as positive control. NTC = no template control.
###end p 52
###begin title 53
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
Correlation of DKK3 promoter methylation with loss of DKK3 mRNA expression
###end title 53
###begin p 54
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 184 189 184 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 322 327 322 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 371 376 371 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 401 406 401 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 437 442 437 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 593 598 593 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 695 700 695 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 232 237 <span type="species:ncbi:9606">human</span>
For all breast carcinoma samples analysed for DKK3 mRNA expression (n = 59) we determined the DKK3 promoter methylation status at the same time. Thus, we were able to directly compare DKK3 methylation and mRNA expression in primary human breast carcinomas. A boxplot (Figure 5) illustrates the distribution and medians of DKK3 RNA expression among normal breast tissues, DKK3 unmethylated tumours and DKK3 methylated tumours. The median DKK3 expression level (exp) of unmethylated tumours (exp = 0.87; FC = 1.2) was comparable with that of normal breast tissues (set to exp = 1). In contrast, DKK3 methylated tumours showed a significant mRNA downregulation (exp = 0.17; FC = 5.9) compared with DKK3 unmethylated tumours and normal breast tissue (global p < 0.001).
###end p 54
###begin p 55
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 0 104 0 104 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Correlation analysis of <italic>DKK3 </italic>promoter methylation with <italic>DKK3 </italic>mRNA expression in primary breast carcinomas</bold>
###xml 143 146 143 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK</italic>
###xml 165 170 165 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 191 196 191 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 245 250 245 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 269 274 269 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
Correlation analysis of DKK3 promoter methylation with DKK3 mRNA expression in primary breast carcinomas. Tumours that are unmethylated in the DKK3 promoter express DKK3 mRNA comparable with DKK3 mRNA expression normal breast tissue, whereas in DKK3 methylated tumours DKK3 mRNA expression is significantly reduced. Horizontal lines = group medians; boxes = 25 to 75% quartiles, range, peak and minimum.
###end p 55
###begin title 56
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
Differential DKK3 protein expression in primary breast carcinomas
###end title 56
###begin p 57
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6a</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6b</xref>
###xml 617 619 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6c</xref>
###xml 711 713 711 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6d</xref>
###xml 724 725 724 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1215 1220 1215 1220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
Immunohistochemical staining was used to investigate DKK3 protein expression in normal (n = 8) and malignant (n = 16) breast tissues. DKK3 was strongly expressed in non-malignant luminal and basal epithelial cells, achieving a mean (sd) immunoreactivity score (IRS) [34] of 11.3 (1.4) (Figure 6a) and a median IRS of 12 (range 9 to 12). DKK3 protein was not detectable in stromal cells in the normal breast tissue. Of the breast carcinomas, four of 16 (25%) revealed abundant DKK3 protein expression (IRS = 9 to 12; Figure 6b) in contrast to seven of 16 tumours (44%), which showed partial loss (IRS = 4 to 8; Figure 6c), and five of 16 tumours (31%) with substantial loss of DKK3 protein (IRS = 0 to 3; Figure 6d and Table 3). The mean protein staining intensity in breast carcinomas was determined to have an IRS of 5.9 (3.3) and the median to have an IRS of 6 (range 0 to 12). DKK3 expression levels in the tumour and normal tissue groups were shown to be significantly different (p = 0.002; U-test), and DKK3 protein was also differentially expressed within the eight matched pairs (p < 0.001; t-test). As a continuous variable, a lower IRS in breast carcinoma was significantly associated with the presence of DKK3 promoter methylation (p = 0.001; Fisher's exact test).
###end p 57
###begin p 58
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 0 98 0 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>DKK3 </italic>protein expression in primary breast carcinomas as determined by immunohistochemical staining</bold>
###xml 100 104 100 104 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 173 178 173 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 197 202 197 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 274 278 274 278 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 313 318 313 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 344 349 344 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 369 373 369 373 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 377 381 377 381 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 417 422 417 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 459 464 459 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
DKK3 protein expression in primary breast carcinomas as determined by immunohistochemical staining. (a) Normal mammary tissue without (left) and with application (right) of DKK3 antibody. Abundant DKK3 protein expression is detectable in luminal and basal epithelial cells. (b) Breast carcinoma with unmethylated DKK3 promoter reveals abundant DKK3 protein expression. (c) and (d) Breast carcinomas with a methylated DKK3 promoter exhibit substantial loss of DKK3 protein expression. Original magnifications are given in upper right-hand corner.
###end p 58
###begin title 59
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
Association of DKK3 promoter methylation with clinicopathological factors
###end title 59
###begin p 60
###xml 99 104 99 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 278 283 278 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 50 57 <span type="species:ncbi:9606">patient</span>
###xml 227 234 <span type="species:ncbi:9606">patient</span>
For descriptive data analysis clinicopathological patient characteristics were correlated with the DKK3 promoter methylation status. In a bivariate analysis, DKK3 promoter methylation was significantly associated with advanced patient age at diagnosis (p = 0.007). Furthermore, DKK3 promoter methylation was not associated with tumour size, lymph node status, histological grade, histological type, and oestrogen receptor or progesterone receptor positivity (data not shown).
###end p 60
###begin title 61
Discussion
###end title 61
###begin p 62
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 227 232 227 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 327 332 327 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 357 362 357 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 398 403 398 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 510 515 510 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 629 634 629 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 684 689 684 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 903 908 903 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1127 1132 1127 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 251 256 <span type="species:ncbi:9606">human</span>
###xml 1220 1225 <span type="species:ncbi:9606">human</span>
It was previously reported that expression of the putative Wnt antagonist DKK3 was downregulated in several tumour entities as a consequence of epigenetic DNA modification [15,16,18,20-22,24]. Our study is the first to analyse DKK3 gene regulation in human breast cancer. Malignant breast cell lines showed strong reduction of DKK3 mRNA in association with DKK3 promoter methylation. Consistently, DKK3 mRNA expression was induced after promoter DNA demethylation in these cells. In primary breast carcinomas, DKK3 mRNA expression was downregulated in 68% of invasive tumours with significant association with methylation of the DKK3 gene promoter (p < 0.001). The total frequency of DKK3 methylation was 61% in breast carcinomas, whereas corresponding normal breast tissues were unaffected by this epimutation. We further showed that a loss of DKK3 protein in breast carcinomas is also associated with DKK3 promoter methylation (p = 0.001) whereas protein expression is abundant in epithelial cells of the normal breast. In summary, our data demonstrate for the first time that promoter methylation-mediated downregulation of DKK3 expression is a frequent and tumour-related epigenetic alteration in the development of human breast cancer.
###end p 62
###begin p 63
###xml 130 132 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 445 451 439 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP1 </italic>
###xml 452 454 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 455 457 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 460 466 454 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 467 469 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 472 478 466 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP5 </italic>
###xml 479 481 473 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 484 489 478 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 490 492 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 498 503 492 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK1 </italic>
###xml 504 506 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 812 817 806 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 891 896 885 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 89 94 <span type="species:ncbi:9606">human</span>
###xml 621 626 <span type="species:ncbi:9606">human</span>
The implication of aberrant canonical Wnt/beta-catenin signalling in the pathogenesis of human cancer has become widely accepted [40]. Its oncogenic effect is mediated by uncontrolled activation of target genes that for example, enhance cell proliferation, such as c-myc and cyclin D1. In breast cancer, several genes encoding inhibitors of canonical Wnt/beta-catenin signalling have been reported to be frequently hypermethylated, for example, SFRP1 [34,41], SFRP2 [42], SFRP5 [43], WIF1 [44] and DKK1 [42]. We suggest that disruption of a non-canonical Wnt signalling branch, the PCP pathway, may also be implicated in human carcinogenesis by pathologically altering the networks of cellular adhesion, motility and cell polarity, because it has been shown that expression of the putative PCP pathway inhibitor DKK3 is commonly downregulated in malignant tissues. As a consequence, loss of DKK3 may promote hyperactivation of the PCP pathway, thereby potentially enhancing tumour aggressiveness.
###end p 63
###begin p 64
###xml 7 15 7 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 140 145 140 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 482 487 482 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 674 676 674 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 889 894 889 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1085 1090 1085 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1279 1284 1279 1284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 127 132 <span type="species:ncbi:10090">mouse</span>
###xml 546 551 <span type="species:ncbi:10090">mouse</span>
###xml 748 753 <span type="species:ncbi:9606">human</span>
###xml 966 974 <span type="species:ncbi:9606">patients</span>
###xml 1071 1079 <span type="species:ncbi:9606">patients</span>
###xml 1351 1359 <span type="species:ncbi:9606">patients</span>
Recent in vivo experiments support a hypothesis that the loss of DKK3 expression promotes an aggressive cancer phenotype. In a mouse model, DKK3 proved to be a promising therapeutic agent to significantly inhibit tumour growth in testicular germ cell cancer [14]. In an orthotopic prostate cancer model a similar treatment resulted in tumour regression, decreased metastasis and prolonged survival of the host [13]. The most recent findings from a breast cancer study revealed that DKK3 not only attenuates tumour growth in a xenotransplantation mouse model, it also re-sensitised multidrug-resistant MCF7/ADR cells to doxorubicin treatment in a JNK-c-Jun dependent manner [26]. This highlights its potential utility as a gene therapeutic agent in human breast cancer. Our study adds important information to this aspect, because it so far remained unknown if methylation-mediated loss of DKK3 expression also occurred in primary breast cancer, and, if so, how many patients were affected by this epimutation. We have shown that a large proportion (61%) of breast cancer patients have DKK3 promoter methylation in the carcinoma tissue, leading to a functional inactivation of the tumour-protective protein. Therefore, we conclude that a potential gene therapeutic treatment with DKK3 might be of benefit for a large target population of breast cancer patients.
###end p 64
###begin p 65
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 301 302 301 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 331 336 331 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 435 440 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 512 513 512 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 613 618 613 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 676 681 676 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
In contrast to other studies, DKK3 promoter methylation in our cohort was not associated with clinicopathological factors indicative of a progressive cancer subtype, such as tumour size, node status or histological grade. The existence of such an association has been demonstrated in prostate cancer [7,12], in which expression of DKK3 was predominantly lost in high-grade prostatic tumours. Moreover, siRNA-mediated downregulation of DKK3 expression in prostate epithelial cells disrupted acinar morphogenesis [7], which taken with its prevalent expression in growth-arrested cells suggests a functional role of DKK3 in post-mitotic tissue differentiation processes. Whether DKK3 is also involved in maintaining glandular morphology in the normal mammary gland will be elucidated in a further study.
###end p 65
###begin p 66
###xml 112 118 112 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP1 </italic>
###xml 122 128 122 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP5 </italic>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 275 280 275 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 686 691 686 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 785 790 785 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 3 8 <span type="species:ncbi:9606">human</span>
###xml 237 244 <span type="species:ncbi:9606">patient</span>
###xml 311 318 <span type="species:ncbi:9606">patient</span>
###xml 611 616 <span type="species:ncbi:9606">human</span>
###xml 747 752 <span type="species:ncbi:9606">human</span>
In human breast cancer, hypermethylation of Wnt antagonist genes was reported to be of clinical relevance. Both SFRP1 and SFRP5 methylation were shown to occur frequently and be tumour specific with a strong association to poor clinical patient outcome [34,43]. An impact of DKK3 promoter methylation on cancer patient survival has been repeatedly found. It was shown to be associated with reduced disease-free survival in acute lymphoblastic leukaemia [20], and also with shorter overall survival in kidney cancer [45] and lung cancer [46]. Due to its functional properties as a potential tumour suppressor in human cancers including breast cancer [26], together with the finding that DKK3 methylation is a significant prognostic factor in three human malignancies, we speculate that DKK3 methylation might also bear prognostic power in breast cancer. This hypothesis is currently being approached in our laboratory in a further study.
###end p 66
###begin p 67
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 181 186 181 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 290 295 290 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 344 349 344 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 131 136 <span type="species:ncbi:9606">human</span>
###xml 317 322 <span type="species:ncbi:9606">human</span>
In summary, we demonstrate for the first time that the Wnt antagonist gene DKK3 is a frequent target of epigenetic inactivation in human breast cancer, leading to downregulation of DKK3 mRNA and DKK3 protein expression in tumourous tissues. These results suggest a causative implication of DKK3 in the development of human breast cancer. Since DKK3 is believed to negatively regulate Wnt signalling, these results underline the pivotal role of a deregulated Wnt signalling pathway commonly found in this disease.
###end p 67
###begin title 68
Conclusion
###end title 68
###begin p 69
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 319 324 319 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 383 388 383 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 86 91 <span type="species:ncbi:9606">human</span>
###xml 362 367 <span type="species:ncbi:9606">human</span>
This study shows that the putative Wnt antagonist DKK3 is frequently downregulated in human breast cancer due to promoter methylation, whereas it is abundantly expressed and unmethylated in normal breast cell epithelium. Since promoter methylation is a primary cause to functionally inactivate tumour suppressor genes, DKK3 may act as a tumour suppressor in the human mammary gland. DKK3 is believed to particularly regulate non-canonical Wnt signalling. Therefore, we conclude that disruption of this Wnt pathway branch may add further tumour growth advantages to those already conferred by canonical Wnt/beta-catenin signalling.
###end p 69
###begin title 70
Abbreviations
###end title 70
###begin p 71
DKK3: Dickkopf-3; FC: fold change; IRS: immunoreactivity score; JNK: c-Jun-kinase; LRP: LDL-receptor related protein; MSP: methylation-specific polymerase chain reaction; PCP: planar cell polarity pathway; RT-PCR: reverse transcription polymerase chain reaction; SD: standard deviation; siRNA: small interfering ribonucleic acid; TSA: trichostatin A.
###end p 71
###begin title 72
Competing interests
###end title 72
###begin p 73
###xml 81 86 81 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
Edgar Dahl has declared that he has submitted a patent application on the use of DKK3 promoter methylation. The other authors have no competing interests.
###end p 73
###begin title 74
Authors' contributions
###end title 74
###begin p 75
JV carried out the gene expression analyses, immunohistochemical studies, methylation experiments and statistical evaluations, participated in the conception and design of the study, and wrote the manuscript. NB participated in the immunohistochemical analysis, performed data interpretation and critically revised the manuscript. AH provided clinical samples and clinicopathological data, performed data interpretation, supported in statistical analyses and critically revised the manuscript. GK provided clinical samples and clinicopathological data, performed data interpretation and critically revised the manuscript. UH provided clinical samples and clinicopathological data, participated in data interpretation and critically revised the manuscript. RK participated in the design and co-ordination of the study and critically revised the manuscript. ED planned and co-ordinated the study, and critically revised the manuscript. All authors have given final approval of the text to be published.
###end p 75
###begin title 76
Acknowledgements
###end title 76
###begin p 77
###xml 283 290 <span type="species:ncbi:9606">patient</span>
###xml 350 355 <span type="species:ncbi:9606">Human</span>
The expert technical assistance of Sevim Alkaya, Sonja von Serenyi and Inge Losen is greatly appreciated. We thank Dr Dieter Niederacher (Heinrich-Heine University, Dusseldorf, Germany) and Professor Matthias Durst (Friedrich-Schiller University, Jena, Germany) for kindly providing patient samples. This work is a research project within the German Human Genome Project and has been supported by a Bundesministerium fur Bildung und Forschung grant 01KW0401 to Edgar Dahl.
###end p 77
###begin article-title 78
Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction
###end article-title 78
###begin article-title 79
###xml 43 48 <span type="species:ncbi:9606">human</span>
Functional and structural diversity of the human Dickkopf gene family
###end article-title 79
###begin article-title 80
LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way
###end article-title 80
###begin article-title 81
LDL-receptor-related protein 6 is a receptor for Dickkopf proteins
###end article-title 81
###begin article-title 82
Kremen2 modulates Dickkopf2 activity during Wnt/LRP6 signaling
###end article-title 82
###begin article-title 83
Wnt signalling in stem cells and cancer
###end article-title 83
###begin article-title 84
Regulation of prostate cell growth and morphogenesis by Dickkopf-3
###end article-title 84
###begin article-title 85
Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer
###end article-title 85
###begin article-title 86
Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway
###end article-title 86
###begin article-title 87
Non-canonical Wnt signalling and regulation of gastrulation movements
###end article-title 87
###begin article-title 88
Vang-like 2 and noncanonical Wnt signaling in outflow tract development
###end article-title 88
###begin article-title 89
###xml 82 87 <span type="species:ncbi:9606">human</span>
Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase
###end article-title 89
###begin article-title 90
Adenovirus-mediated REIC/Dkk-3 gene transfer inhibits tumor growth and metastasis in an orthotopic prostate cancer model
###end article-title 90
###begin article-title 91
###xml 57 62 <span type="species:ncbi:9606">human</span>
REIC/Dkk-3 as a potential gene therapeutic agent against human testicular cancer
###end article-title 91
###begin article-title 92
Reduced expression of REIC/Dkk-3 gene in non-small cell lung cancer
###end article-title 92
###begin article-title 93
###xml 74 79 <span type="species:ncbi:9606">human</span>
Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells
###end article-title 93
###begin article-title 94
Antiproliferative activity of REIC/Dkk-3 and its significant down-regulation in non-small-cell lung carcinomas
###end article-title 94
###begin article-title 95
###xml 38 43 <span type="species:ncbi:9606">human</span>
Decreased expression of REIC/Dkk-3 in human renal clear cell carcinoma
###end article-title 95
###begin article-title 96
Dickkopf-3/REIC functions as a suppressor gene of tumor growth
###end article-title 96
###begin article-title 97
Transcriptional silencing of the Dickkopfs-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic leukaemia
###end article-title 97
###begin article-title 98
Functional epigenomics identifies genes frequently silenced in prostate cancer
###end article-title 98
###begin article-title 99
Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection
###end article-title 99
###begin article-title 100
Expression of Dickkopf genes is strongly reduced in malignant melanoma
###end article-title 100
###begin article-title 101
###xml 61 66 <span type="species:ncbi:9606">human</span>
Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors
###end article-title 101
###begin article-title 102
Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung
###end article-title 102
###begin article-title 103
REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer
###end article-title 103
###begin article-title 104
###xml 37 42 <span type="species:ncbi:9606">human</span>
###xml 66 71 <span type="species:ncbi:9606">human</span>
A REIC gene shows down-regulation in human immortalized cells and human tumor-derived cell lines
###end article-title 104
###begin article-title 105
###xml 49 54 <span type="species:ncbi:9606">human</span>
Early events during neoplastic transformation of human cells in vitro: Genetic and biological aspects of immortalization
###end article-title 105
###begin article-title 106
Dickkopf genes are co-ordinately expressed in mesodermal lineages
###end article-title 106
###begin article-title 107
Characterization of epithelial senescence by serial analysis of gene expression: identification of genes potentially involved in prostate cancer
###end article-title 107
###begin article-title 108
Method for grading breast cancer
###end article-title 108
###begin article-title 109
Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis
###end article-title 109
###begin article-title 110
[Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]
###end article-title 110
###begin article-title 111
DNA methylation and cancer
###end article-title 111
###begin article-title 112
Aberrant DNA methylation as a cancer-inducing mechanism
###end article-title 112
###begin article-title 113
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands
###end article-title 113
###begin article-title 114
Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia
###end article-title 114
###begin article-title 115
Wnt signaling and cancer
###end article-title 115
###begin article-title 116
###xml 84 89 <span type="species:ncbi:9606">human</span>
Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer
###end article-title 116
###begin article-title 117
Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer
###end article-title 117
###begin article-title 118
###xml 83 88 <span type="species:ncbi:9606">human</span>
Epigenetic inactivation of the Secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis
###end article-title 118
###begin article-title 119
Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer
###end article-title 119
###begin article-title 120
Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA
###end article-title 120
###begin article-title 121
Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer
###end article-title 121

